MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
Phase 2
Not yet recruiting
- Conditions
- Hypomagnesemia in Type 2 Diabetic Patients
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Pharmalyte Solutions LLC
- Target Recruit Count
- 200
- Registration Number
- NCT03567824
MLD10 in the Prevention of Migraine in Adults
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Pharmalyte Solutions LLC
- Target Recruit Count
- 157
- Registration Number
- NCT02322333
- Locations
- 🇺🇸
Westside Family Medical Center, P.C., Kalamazoo, Michigan, United States
🇺🇸The Research Center of Southern California, Carlsbad, California, United States
🇺🇸Dr. B. Abraham, P.C., Snellville, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath